Cargando…
Flubendazole inhibits PD-1 and suppresses melanoma growth in immunocompetent mice
BACKGROUND: Immune checkpoint inhibitor therapy has revolutionized the clinical management of a diverse range of cancer types, including advanced cutaneous melanoma. While immunotherapy targeting the PD-1/PD-L1 system has become standard of care, overall response rates remain unsatisfactory for most...
Autores principales: | Li, Yue, Wu, Ben, Hossain, Md Jakir, Quagliata, Lily, O’Meara, Connor, Wilkins, Marc R., Corley, Susan, Khachigian, Levon M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349441/ https://www.ncbi.nlm.nih.gov/pubmed/37452307 http://dx.doi.org/10.1186/s12967-023-04289-y |
Ejemplares similares
-
Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
por: O’Meara, Connor H., et al.
Publicado: (2023) -
Flubendazole as a macrofilaricide: History and background
por: Geary, Timothy G., et al.
Publicado: (2019) -
Toxicity of anthelmintic drugs (fenbendazole and flubendazole) to aquatic organisms
por: Wagil, Marta, et al.
Publicado: (2014) -
Transcription Factors Targeted by miRNAs Regulating Smooth Muscle Cell Growth and Intimal Thickening after Vascular Injury
por: Khachigian, Levon M.
Publicado: (2019) -
Pharmaceutical patents: reconciling the human right to health with the incentive to invent
por: Khachigian, Levon M.
Publicado: (2020)